Design Therapeutics Inc DSGN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if DSGN is a good fit for your portfolio.
News
-
Design Therapeutics Outlines Progress Across GeneTAC™ Platform and Announces Fourth Quarter and Full Year 2023 Financial Results
-
Design Therapeutics to Webcast Fourth Quarter and Full Year 2023 Financial Results and Comprehensive Portfolio Update
-
Design Therapeutics stock plunges on trial results for neuromuscular disease treatment
Trading Information
- Previous Close Price
- $3.74
- Day Range
- $3.68–3.90
- 52-Week Range
- $1.94–8.47
- Bid/Ask
- $2.52 / $4.01
- Market Cap
- $209.03 Mil
- Volume/Avg
- 388,557 / 271,724
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company’s product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 124
- Website
- https://www.designtx.com
Comparables
Valuation
|
Metric
|
DSGN
|
GBIO
|
CBAY
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 0.76 | 0.91 | 12.65 |
Price/Sales | — | 30.36 | 111.01 |
Price/Cash Flow | — | — | — |
Price/Earnings
DSGN
GBIO
CBAY
Financial Strength
|
Metric
|
DSGN
|
GBIO
|
CBAY
|
|---|---|---|---|
Quick Ratio | 29.44 | 6.73 | 10.70 |
Current Ratio | 29.58 | 6.83 | 10.96 |
Interest Coverage | — | — | −5.27 |
Quick Ratio
DSGN
GBIO
CBAY
Profitability
|
Metric
|
DSGN
|
GBIO
|
CBAY
|
|---|---|---|---|
Return on Assets (Normalized) | −17.16% | −25.96% | −30.06% |
Return on Equity (Normalized) | −17.93% | −40.85% | −51.97% |
Return on Invested Capital (Normalized) | −17.73% | −34.11% | −30.87% |
Return on Assets
DSGN
GBIO
CBAY
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Yxkqtrpj | Xzw | $550.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Xkpgcsd | Lvkbyk | $101.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Ghtbbltx | Qgtsmw | $98.1 Bil | |
MRNA
| Moderna Inc | Bkqjtjhz | Wvvqx | $39.1 Bil | |
ARGX
| argenx SE ADR | Gmclbbhxf | Klhs | $21.7 Bil | |
BNTX
| BioNTech SE ADR | Yjtjkyl | Gsvs | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Gxqmbzhz | Xjmljq | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Xkshlbms | Gcntb | $17.1 Bil | |
RPRX
| Royalty Pharma PLC Class A | Zmxnjshmf | Rkqwrfn | $12.5 Bil | |
INCY
| Incyte Corp | Djzzhwlyp | Zdshsx | $11.9 Bil |